Ocrelizumab initiation in patients with MS: A multicenter observational study

OBJECTIVE: To provide first real-world experience on patients with MS treated with the B cell–depleting antibody ocrelizumab. METHODS: We retrospectively collected data of patients who had received at least 1 treatment cycle (2 infusions) of ocrelizumab at 3 large neurology centers. Patients' c...

Descripción completa

Detalles Bibliográficos
Autores principales: Ellwardt, Erik, Rolfes, Leoni, Klein, Julia, Pape, Katrin, Ruck, Tobias, Wiendl, Heinz, Schroeter, Michael, Zipp, Frauke, Meuth, Sven G., Warnke, Clemens, Bittner, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176249/
https://www.ncbi.nlm.nih.gov/pubmed/32273482
http://dx.doi.org/10.1212/NXI.0000000000000719

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176249/
https://www.ncbi.nlm.nih.gov/pubmed/32273482
http://dx.doi.org/10.1212/NXI.0000000000000719

Ejemplares similares